NGLFINENGL Fine-Chem Limited
Convert to ideaHealthcare · Pharmaceuticals
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeUp 0.6 this quarter.
Momentum from moving averages, Supertrend and RSI.
2 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
2 found · risk elevated
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹159 Cr | ₹16 Cr | 13.55% | 10.24% | ₹26.30 | 20.3x |
| Q1 FY2027 | ₹139 Cr | ₹18 Cr | 12.96% | 13.22% | ₹29.78 | 26.0x |
| Q4 FY2026 | ₹149 Cr | ₹13 Cr | 10.96% | 9.04% | ₹21.83 | 18.6x |
| Q3 FY2026 | ₹128 Cr | ₹16 Cr | 13.43% | 12.31% | ₹25.40 | 20.3x |
| Q2 FY2026 | ₹120 Cr | ₹10 Cr | 10.04% | 8.00% | ₹15.58 | 12.2x |
| Q1 FY2026 | ₹104 Cr | ₹9 Cr | 6.44% | 8.87% | ₹14.96 | 10.7x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.